Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, the findings from our study may assist future development of G-quadruplex-specific ligands in the treatment of neurodegenerative diseases like ALS and FTD.
|
31800202 |
2020 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
TDP-43 aggregates are a salient feature for ALS, FTD and a variety of other neurodegenerative diseases including AD.
|
31846303 |
2020 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting the UPR/ISR may be beneficial in mtSOD1-induced ALS as well as other neurodegenerative diseases in which misfolded proteins and ER stress have been implicated.
|
31837419 |
2020 |
Neurodegenerative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Epidemiological data have linked cadmium exposure to neurotoxicity and to neurodegenerative diseases (e.g., Alzheimer's and Parkinson's disease), and to increased risk of developing ALS.
|
31738976 |
2020 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Insoluble, hyperubiquitylated TAR DNA binding protein of 43 kDa (TDP-43) in the central nervous system characterizes frontotemporal dementia and ALS in many individuals with these neurodegenerative diseases.
|
31780563 |
2020 |
Neurodegenerative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutations in the copper (Cu)- and zinc (Zn)-binding metalloenzyme Cu/Zn-superoxide dismutase (SOD1) cause familial forms of amyotrophic lateral sclerosis (ALS), a fatal adult-onset neurodegenerative disorder of the central nervous system (CNS).
|
30255176 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Cerebrospinal fluid (CSF) from patients including sALS as well as several other neurodegenerative diseases and non-neurodegenerative diseases was examined with an immunoprecipitation assay and a sandwich ELISA using antibodies specifically recognizing misfolded SOD1.
|
31744522 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Oxidative stress plays a critical role in mutant copper/zinc superoxide dismutase 1 (SOD1)-linked amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease characterized by selective loss of motor neurons.
|
31521619 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The process of misfolding and aggregation of neuronal proteins such as α-synuclein, Tau, amyloid beta (Aβ), TDP-43 or SOD1 is a common hallmark of many neurodegenerative disorders and iron has been shown to facilitate protein aggregation.
|
30723395 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Over the past decade, SILK studies have been used to determine the turnover of key pathogenic proteins amyloid-β (Aβ), tau and superoxide dismutase 1 (SOD1) in the cerebrospinal fluid of healthy individuals, patients with AD and those with other neurodegenerative diseases.
|
31222062 |
2019 |
Neurodegenerative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutations in superoxide dismutase (SOD1) are the second most common cause of familial amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease caused by the death of motor neurons in the brain and spinal cord.
|
31474832 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Induced-fit complexation is reliant on the structural plasticity of the immature SOD1 disulphide sub-loop, a characteristic which contributes to misfolding and aggregation in neurodegenerative disease.
|
30735496 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Repeat-associated non-AUG (RAN) translation is a noncanonical translation initiation event that occurs at nucleotide-repeat expansion mutations that are associated with several neurodegenerative diseases, including fragile X-associated tremor ataxia syndrome (FXTAS), ALS, and frontotemporal dementia (FTD).
|
31649034 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, human genetic evidence has linked the dysregulation of RIPK1 to the pathogenesis of ALS as well as other inflammatory and neurodegenerative diseases.
|
31048504 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
SOD1 misfolding and aggregation is correlated with cytotoxicity in neurodegenerative diseases such as amyotrophic lateral sclerosis.
|
30654299 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
To illustrate the application of these methods we report to our previous studies on misfolding, aggregation and amyloid fibril formation by superoxide dismutase 1 (SOD1), a protein whose toxic deposition is implicated in the neurodegenerative disease amyotrophic lateral sclerosis (ALS).
|
30341600 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Dozens of mutations throughout the sequence of the gene encoding superoxide dismutase 1 (SOD1) have been linked to toxic protein aggregation in the neurodegenerative disease amyotrophic lateral sclerosis (ALS).
|
31341015 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
ALS is an incurable neurodegenerative disorder, with the recommendation that symptom management and palliative care start immediately or soon after diagnosis.
|
31520967 |
2019 |
Neurodegenerative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<b>Background:</b> Pathogenic variants in ALS genes are known to be present in up to 70% of familial and 10% of apparently sporadic ALS cases, and can be associated with risks for ALS only, or risks for other neurodegenerative diseases (eg. frontotemporal dementia).
|
31702461 |
2019 |
Neurodegenerative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutations in superoxide dismutase (SOD1) cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the loss of upper and lower motor neurons.
|
31262807 |
2019 |
Neurodegenerative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Amyotrophic lateral sclerosis is one such devastating neurodegenerative disorder characterized by mutation in Cu/Zn superoxide dismutase protein (SOD1).
|
31422280 |
2019 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Immune inflammatory modulation as a potential therapeutic strategy of stem cell therapy for ALS and neurodegenerative diseases.
|
30463642 |
2018 |
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The neurotoxin β-<i>N</i>-methylamino-l-alanine (BMAA), a non-protein amino acid produced by terrestrial and aquatic cyanobacteria and by micro-algae, has been suggested to play a role as an environmental factor in the neurodegenerative disease Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia complex (ALS-PDC).
|
29443939 |
2018 |
Neurodegenerative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Oxidative stress exhibits a central role in the course of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease commonly found to include a copper/zinc superoxide dismutase (SOD1) gene mutation.
|
29559385 |
2018 |
Neurodegenerative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Degeneration of cortical and spinal motor neurons is the typical feature of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease for which a pathogenetic role for the Cu/Zn superoxide dismutase (SOD1) has been demonstrated.
|
30154836 |
2018 |